Transforming access to esophageal care
We are a leading gastrointestinal health company delivering minimally invasive diagnostics for everyone, everywhere.
Explore
Impact
Earlier matters
Esophageal cancer is one of the fastest-growing cancers. Barrett's Esophagus is the only known precursor to Esophageal Adenocarcinoma, yet fewer than 10% of patients have a prior diagnosis.
Only
1 in 5
people with esophageal
cancer survive their diagnosis
cancer survive their diagnosis
EndoSign® is a minimally-invasive capsule sponge device that enables safe and accessible cell collection with full esophageal sampling.
Learn more about our advanced molecular diagnostics:
Recent news
View All
25
March 2025
Cyted Health Expands US Presence with First Patients Enrolled in DETECT-ME Clinical Validation Study
Read more
No items found.
21
March 2025
Cyted Health Awarded Best Provider of Diagnostic Services at HSJ Partnership Awards 2025
Read more
No items found.
19
February 2025
Cyted Health Awarded Grant to Transform Early Detection of Oesophageal Cancer in Wales and Northern Ireland
Read more
No items found.
Get in touch for more information about our early cancer test and data-driven diagnostics.
Get in touch
